Infliximab for the treatment of paediatric Crohn's disease: Obstacles to accessing a necessary therapy

Paediatrics and Child Health

Volumn 9, Issue 2, 2004, Pages 87-89

  Otley, Anthony ^a,d   Critch, Jeff ^b   Butzner, J Decker ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d IWK HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

CLINICAL TRIAL; COLON RESECTION; COST BENEFIT ANALYSIS; CROHN DISEASE; DRUG APPROVAL; DRUG CHOICE; DRUG INDICATION; DRUG INFUSION; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; ILEOSTOMY; INFECTION SENSITIVITY; MEDICAL CARE; NOTE; PATHOPHYSIOLOGY; RELAPSE; RISK ASSESSMENT; SEPSIS; SERUM SICKNESS; SIDE EFFECT; TUBERCULOSIS; ULCERATIVE COLITIS;

EID: 1642296258     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/9.2.87     Document Type: Note

References (30)

1. Holloway H, Mullen W, Fielding JF. Who best assesses Crohn's disease? Ir J Med Sci 1996;165:95-8.
2. Ferguson A, Sedgwick DM, Drummond J. Morbidity of juvenile onset inflammatory bowel disease: Effects on education and employment in early adult life. Gut 1994;35:665-8.
3. Gryboski J. Ulcerative colitis in children 10 years or younger. J Pediatr Gastroenterol Nutr 1993;17:24-31.
4. Gryboski JD. Crohn's disease in children 10 years old and younger: Comparison with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994;18:174-82.
5. Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three-fold rise in Crohn's disease. Gut 1989;30:618-22.
6. Mir-Madjlessi SH, Michener WM, Farmer RG. Course and prognosis of idiopathic ulcerative proctosigmoiditis in young patients. J Pediatr Gastroenterol Nutr 1986;5:570-5.
7. Griffiths AM. Inflammatory bowel disease. Adolesc Med 1995;6:351-68.
8. Sherman PM, Griffiths A, Marcon M, Smith C, Geist R. Lifestyle issues in children and adolescents with chronic inflammatory bowel diseases. Can J Gastroenterol 1990;4:364-8.
9. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
10. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
11. Dick A, Keady S, Mohamed F, et al. Use of unlicensed and off-label medications in paediatric gastroenterology with a review of the commonly used formularies in the UK. Aliment Pharmacol Ther 2003;17:571-5.
12. Khaled LA. Prescription use by a million Canadian children. Paediatr Child Health 2003;8(Suppl A):6A.
13. Repchinsky C, ed. Compendium of Pharmaceuticals and Specialities. Ottawa: Canadian Pharmacists Association, 2003:167,406-8,523,575, 787,980,985,1275,1401,1533-5.
14. Schirm E, Tobi H, de Jong-van den Berg LT. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 2003;111:291-5.
15. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823-8.
16. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000;137:192-6.
17. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: Frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84.
18. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8.
19. Matsui D, Kwan C, Steer E, Rieder MJ. The trials and tribulations of doing drug research in children. CMAJ 2003;169:1033-4.
20. Hanauer SB. Review article: Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999;13(Suppl 4):16-22,38.
21. Feagan BG, Enns R, Fedorak RN, et al. Infliximab for the treatment of Crohn's disease: Efficacy, safety and pharmacoeconomics. Can J Clin Pharmacol 2001;8:188-98.
22. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother 2003;37:1256-65.
23. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
24. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: A user's guide for clinicians. Am J Gastroenterol 2002;97:2962-72.
25. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
26. Pediatric Research Equity Act of 2003. 〈 www.theorator.com/bills108/s650.html〉 (Version current at January 16, 2004).
27. Thompson TG, McClellan MB. Passage of S650, the Pediatric Research Equity Act of 2003. FDA Statement. 〈 www.fda.gov/bbs/topics/NEWS/2003/NEW00979.html〉 (Version current at January 16, 2004).
28. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003;3:81-92.
29. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT 1 randomised trial. Lancet 2002;359:1541-9.
30. Panaccione R. Infliximab for the treatment of Crohn's disease: Review and indications for clinical use in Canada. Can J Gastroenterol 2001;15:371-5.